Evaluating only Genocea-style cautionary: Miraca Life Sciences spinoff Veracyte vs Neon Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
Founded in Cambridge, MA, with backing from Third Rock Ventures to develop personalized neoantigen vaccines.
FUNDING
Raised $55M Series B and signed clinical collaboration with Bristol-Myers Squibb to combine with Opdivo.
PRODUCT LAUNCH
NEO-PV-01 Phase 1b data showed T-cell responses but no overall survival benefit; BMS declined to expand.
SHUTDOWN
Neon wound down operations and transferred research assets to Agenus after failing to raise Series C.
Full Analysis
Free · no account needed
Documented cause
Neon Therapeutics developed personalized neoantigen cancer vaccines. After raising $147M and establishing clinical partnerships with Bristol-Myers Squibb, Phase 1/2 data for NEO-PV-01 in 2020 showed immune responses but no clear survival benefit versus checkpoint inhibitors alone. BMS declined to advance the partnership. Unable to raise Series C capital in 2021, Neon wound down and merged assets into Agenus in early 2022.
Lesson
“Pharma partnership exits are death signals — build clinical data independence before relying on big-pharma validation.”
// engine intelligence on Genocea-style cautionary: Miraca Life Sciences spinoff Veracyte vs Neon Therapeutics
Tier 1 · instant unlock🔒 free account
Loading engine analysis…
Tier 2 · the productAnalyst · €149/mo
What you see retrospectively on Genocea-style cautionary: Miraca Life Sciences spinoff Veracyte vs Neon Therapeutics, applied predictively to your companies:
→Cross-reference this pattern against your live portfolio
→Alerts when a company you track starts matching this profile